Patient-Specific BBB, Built for Precision.
We deliver high-throughput, iPSC-derived BBB assembloids built on 10+ years of scientific rigor and published academic research. Our modular, reproducible BBB assays adapt to your therapeutic area — bringing human-relevant neurovascular insight directly into your CNS drug discovery pipeline. Every study is executed exclusively by our expert scientific team, ensuring the highest quality control, assay reproducibility, and data reliability.
Have a CNS project in mind? Contact our team to discuss study design, timelines and how NeuroSkye can support your BBB needs.
Beyond Permeability. We Provide Predictability.
NeuroSkye delivers robustly validated, mechanistically predictive BBB data through our rigorously standardized human assembloid workflows. We reveal not just whether molecules cross — but how and why they succeed or fail, empowering confident and faster selection of CNS therapeutics.
Your Gateway Through the BBB.
Traditional CNS models fall short in replicating the full complexity of the human BBB. NeuroSkye’s human BBB assembloid assays deliver barrier insight and predictive power — combining high-throughput scalability (thousands of uniform assembloids produced at a time), >98% reproducibility, and NAM-aligned, non-animal workflows at low cost.
Built for the Future of Drug Development.
NeuroSkye’s New Approach Methodologies (NAMs) support ethical, human-relevant, and regulation-ready drug development for CNS, oncology, neuroinflammation, aligning with evolving FDA and global regulatory expectations.
Less Guesswork. More Go/No-Go Confidence.
Our in vitro blood-brain barrier models are built for high-throughput drug screening and already helping teams make faster, data-driven go/no-go decisions. From brain cancer to neurodegeneration diseases, our modular systems are adaptable, scalable, and ready to transform CNS discovery.
